IZAR-1 Hits Week 16 Endpoints; Q3 Loss Wider Than Expected at $0.93/Share
MLTX sits 23% above its 52-week low of $9.46.
Summary
MoonLake's Phase 3 IZAR-1 trial met its Week 16 endpoints, the key efficacy readout for sonelokimab in hidradenitis suppurativa. That follows the BLA submission disclosed in the September 30 8-K and keeps the FDA decision timeline intact. The Q3 print was messier: net loss of $79.5 million, or $0.93 per share, came in wider than the $0.78 consensus, though cash and short-term investments of $498.5 million fund operations into mid-2028. Next catalysts are IZAR-2 results in Q1 2027 and IZAR-1 Week 52 data in Q2 2027, with VELA-TEEN Phase 3 completing in Q4 2026 and reading out Q1 2027. A US launch of sonelokimab is planned for H2 2027 pending approval.
At the time of this announcement, MLTX was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $981.3M. The 52-week trading range was $9.46 to $23.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.